Contineum Therapeutics, Inc. Class A Common Stock (CTNM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a cash flow conversion efficiency ratio of -0.068x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.20 Million) by net assets ($180.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Contineum Therapeutics, Inc. Class A Common Stock - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Contineum Therapeutics, Inc. Class A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CTNM liabilities breakdown for a breakdown of total debt and financial obligations.
Contineum Therapeutics, Inc. Class A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Contineum Therapeutics, Inc. Class A Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Increase Technology Co Ltd Class A
SHE:300713
|
0.057x |
|
Melcor Developments Ltd.
TO:MRD
|
-0.004x |
|
Enviro Infra Engineers Ltd
NSE:EIEL
|
-0.092x |
|
Suzhou Fushilai Pharmaceutical Co. Ltd.
SHE:301258
|
N/A |
|
Zhejiang HISUN Biomaterials Co. Ltd. A
SHG:688203
|
N/A |
|
Frp Holdings Ord
NASDAQ:FRPH
|
0.017x |
|
DI Dong Il Corp
KO:001530
|
-0.021x |
|
HOMAG Group AG
F:HG1
|
0.046x |
Annual Cash Flow Conversion Efficiency for Contineum Therapeutics, Inc. Class A Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see CTNM market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $198.07 Million | $-32.84 Million | -0.166x | +41.78% |
| 2023-12-31 | $-67.94 Million | $19.35 Million | -0.285x | +44.41% |
| 2022-12-31 | $39.27 Million | $-20.12 Million | -0.512x | -20.14% |
| 2021-12-31 | $61.59 Million | $-26.27 Million | -0.426x | -- |
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idio… Read more